(PubMed) Levy MM, Fink MP, Marshall JC, et al
The new results suggest but dont prove that the weight-loss medications may be able to target the underlying source of cravings that affect the more than 48 million Americans with substance use disorders
GLP-1 Receptor Agonist Market Share Companies such as Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi dominate this market due to their strong research capabilities, innovative drug formulations, and commitment to addressing diabetes and obesity challenges
4 Cardiovascular Risk Reduction In addition to managing blood glucose levels and promoting weight loss, GLP-1 receptor agonists have been found to reduce the risk of cardiovascular events, which is a critical consideration in diabetic patients
Using the UK Biobank as a global reference of worldwide populations: application to measuring ancestry diversity from GWAS summary statistics
1992 Sep;35(9):813-7